Top Section/Ad
Top Section/Ad
Most recent
Offer came as markets recovered and volatility fell
Abbott Laboratories plundered $20bn as it led a trio of drug companies which printed jumbo bonds as a deluge of supply in the dollar market ensured a red-hot end to the month.
Eight banks provided loan facility to company
More articles/Ad
More articles/Ad
More articles
-
Synairgen, the UK biopharmaceuticals company, has raised £80m from investors to fund the next stage of clinical trials for a treatment designed to alleviate the respiratory symptoms of Covid-19. -
Oil prices, which are key to the public finances of many MENA states, have recovered somewhat since their abrupt slump earlier this year but experts are not optimistic they will regain the levels seen at the start of 2020
-
Aedifica, the Belgian healthcare real estate investment company, which owns a portfolio of care homes, has launched a €459m rights issue to fund an acquisition and to grow its development pipeline. Sources close to the deal are confident that the cash call will be popular given investor demand for exposure to speciality real estate businesses.
-
Wilhelm Beier, the German billionaire founder of Dermapharm Holding, has trimmed his stake in the pharmaceuticals company.
-
Zambia looks set to be Africa’s first sovereign to default due to the coronavirus crisis. This already complex situation could be being made even more complicated by China — a big bilateral lender to Zambia.
-
Morphosys, the German biotech company, has tapped the equity-linked market with a new €325m convertible bond, adding to the flood of issuance from the sector during the pandemic.
